Cheers Mozz
This is kind of in response to a discussion on another thread (on temazumab) but is really about the different trials so thought I would post here.
Took some time to unpick the trial design for these one registered so far.
002 -
https://clinicaltrials.gov/ct2/show/record/NCT04809376006 -
https://clinicaltrials.gov/ct2/show/record/NCT04814719008 -
http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381039Summarised here with a bit of license used to abbreviate some of the endpoints. Might help to understand some of the thinking in how they all interact (so when you work it out please let me know
. But just a couple of observations...
- 008 also contains many of the key endpoints in the pivotal 002 (hence the 'lookthrough' for potential partnering discussions).
- 006 doesnt seem to have biomarker data?
- 008 also looking at biomarkers in serum and urine. I wonder if they are trying to correlate that to synovial fluid data, then possibly adding it to 006 (if it correlates well much easier to measure that than synovial fluid).
- 002 has changes in ECG which is a new one
(20min delay)